TEVA Teva Pharmaceutical Industries Limited logo

TEVA Teva Pharmaceutical Industries Limited

Healthcare
$34.61+1.58%ClosedMarket Cap: $40.30B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

24.24

PEG

0.13

P/B

4.91

P/S

2.36

EV/EBITDA

16.39

DCF Value

$20.87

FCF Yield

4.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

52.0%

Operating Margin

19.4%

Net Margin

9.0%

ROE

20.8%

ROA

3.9%

ROIC

11.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$3.98B$369.0M$
Q4 null$4.71B$480.0M$
FY null$17.26B$1.41B$
Q3 null$4.48B$433.0M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$39.29

Target (Median)

$40.00

Target Range

$35.00 - $42.00

4 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell
BarclaysOverweight
2026-05-06
JP MorganOverweight
2026-04-30
Truist SecuritiesBuy
2026-04-30
UBSBuy
2026-04-30
Piper SandlerOverweight
2026-04-30

Trading Activity

Insider Trades

View All
Lippman Evanofficer: EVP, Business Development
SellMon May 18
Lippman Evanofficer: EVP, Business Development
SellMon May 18
Lippman Evanofficer: EVP, Business Development
SellMon May 18
Lippman Evanofficer: EVP, Business Development
SellMon May 18
Kalif Eliyahu Sharonofficer: EVP, Chief Financial Officer
SellMon May 18

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

IL

Exchange

Beta

0.86

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Peers